![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, November 10, 2021 11:46:10 PM
~ Mathieu, Y@h00 RLFTF finance conversations
——————————————
Reply
My concern is with the FDA's approval of the Trial Plan. They upwardly revised the pln to 196 knowing full well that would be on a 2:1 treatment/placebo ratio thereby only rendering 131 "treated" (with aviptadil) patients.
Per Nrx's June 25th 2021 S-1 filing, p.75:
"The Intravenous Trial was originally conceived by us and approved by the FDA as a 28-day clinical trial."
"In December 2020, prior to unblinding, we recognized that one-third of the patients participating in the trial were still in the ICU at 28 days and notified the FDA of the need for a 60-day endpoint. The FDA amended its guidance to assess 196 participants to a primary endpoint at 60 days prior to patient-level unblinding."
"The FDA’s February 2021 guidance included a mandate to consider treatment site effects."
https://www.sec.gov/Archives/edgar/data/1719406/000119312521200558/d175615ds1.htm#tx175615_12
So instead of owning up to the error in guidance they just dumped it on Nrx & RL.
This is not the first time they did this. Look at this prior post on Reddit:
"Is a trial of 196 patients enough? Merck previously tried for an EUA for their drug due to results based off a trial with around 200 patients but the FDA decided to hold off until they received more data."
https://www.reddit.com/r/COVID19/comments/npttvu/nrx_pharmaceuticals_announces_positive_results/
~ Zorro, Y@h00 RLFTF finance conversations
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM